Abstract. Azithromycin has been widely used for the treatment of Treponema pallidum. However, the drug resistance of T. pallidum for azithromycin is currently increasing.
Introduction
Syphilis is a sexually transmitted disease caused by infection with the spirochete Treponema pallidum (1, 2) . Previous studies have indicated that the occurrence of syphilis may result in severe complications, including dermatological diseases, neurosyphilis and cardiovascular syphilis, which remain key causes of morbidity worldwide (3, 4) . In addition, syphilis facilitates the infectivity and susceptibility to HIV infection in the clinic (5) . Currently, the incidence of syphilis is increasing in multiple developed countries (6, 7) . Although various treatments have been explored, including antibiotic therapy and antiviral therapy, these regimens are unsatisfactory, particularly in specific populations (8, 9) . Therefore, early diagnosis and effective treatment of patients at the early stage of syphilis are essential for inhibition of T. pallidum infection.
Previous reports have indicated that antibiotic desensitization protocols may facilitate optimal and safe antibiotic therapy in the appropriate clinical setting for patients with T. pallidum infection (10) . Alternative antibiotics treatments are widely used for patients with syphilis who are allergic to penicillin, including doxycycline, tetracycline, ceftriaxone, erythromycin and azithromycin (11, 12) . Clinical trials have indicated that the efficacy of oral administration of azithromycin (2.0 g) is equivalent to that of benzathine penicillin G for the treatment of early syphilis in patients without HIV infection (13) . However, drug resistance of T. pallidum for azithromycin attenuates its therapeutic efficacy for patients with syphilis (14) . Molecular analysis has indicated that the acidic repeat protein (arp) gene, T. pallidum repeat (tpr) gene and tp0548 gene are associated with the drug resistance of T. pallidum (15, 16) . Therefore, it is critical to analyze the association between gene subtypes of T. pallidum and drug resistance of azithromycin.
The objectives of this study were to analyze the association between gene subtype of T. pallidum and drug resistance to azithromycin. In this study, tpr-positive specimens were analyzed for the presence of A2058G and A2059G mutations and the relative drug resistance to azithromycin was determined among T. pallidum strains.
Materials and methods
Sample collection and molecular strain typing. A total of 132 blood samples were collected from female patients from the Yongkang region with primary syphilis in The First People's Hospital of Yongkang (Zhejiang, China) between May 2016 and June 2017. Patients with HIV or T. pallidum history were excluded from the present study. The protocols were approved by the Human Subjects Division of The First People's Hospital of Yongkang. All patients were required to provide written informed consent. T. pallidum strains were isolated from patient blood samples using sequencing-based typing or enhanced Centers for Disease Control and Prevention typing as described previously (17) . DNA samples were tested for T. pallidum using quantitative polymerase chain reaction (PCR) targeting the polA gene (18) .
DNA extraction. T. pallidum DNA was isolated as previously described (19) . Briefly, DNA was extracted from 200 µl of whole blood and DNAzol (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) was used to extract DNA from specimens, according to the manufacturer's protocols. Strain typing was classified based on the analysis of three DNA target regions: (1) Restriction fragment length polymorphism analysis of sequence differences in the tpr gene; (2) the number of 60 bp repeats in the arp gene; (3) sequence analysis of a short region of the tp0548 gene (20) .
PCR methods. The PCR assay for T. pallidum analyzed the gene target polA as described previously (21) . The primers used were as follows: F: 5'-CGT GTG GTA TCA ACT ATG G-3' , R: 5'-TCA ACC GTG TAC TCA GTG C-3'. All PCR products were analyzed using an ABI9700 GeneAmp PCR system (Applied Biosystems; Thermo Fisher Scientific, Inc.). PCR was performed in a 25 µl reaction volume with 0.1 µg DNA, 1.5 mM MgCl 2 , 0.2 mM dNTP, 0.5 µM primers and 0.5 µl Taq polymerase (Takara Bio, Inc., Otsu, Japan). PCR conditions were as follows: 96˚C for 5 min, followed by 40 cycles at 95˚C for 30 sec, 56˚C for 56 sec and 72˚C for 60 sec, followed by 72˚C for 600 sec. PCR products were analyzed on a 1.5% agarose gel. Then, PCR products were visualized by staining with ethidium bromide and comparing with the molecular size markers of a 100-or 2,000-bp ladder (New England BioLabs, Inc., Ipswich, MA, USA).
Detection of drug resistance to azithromycin. The polA gene was amplified to detect resistance to azithromycin (22) . Briefly, PCR amplification of the 23S rRNA gene of T. pallidum was treated by restriction enzyme digestion (MboII) as described previously (23, 24) . PCR were performed in a 50 µl reaction volume with 0.2 µg rRNA, 1.5 mM MgCl 2 , 0.2 mM dNTP, 0.5 µM primers (5'-GTGCCAGCMGCCGCGG-3') and 1.0 µl Taq polymerase. PCR conditions were as follows: 95˚C for 5 min, followed by 35 cycles at 94˚C for 30 sec, 54˚C for 57 sec and 72˚C for 60 sec, followed by 72˚C for 600 sec. The azithromycin resistance genotypes were analyzed by DNA sequencing of the PCR products after purification with a QIAquick PCR purification kit (Qiagen, Inc., Valencia, CA, USA). T. pallidum DNA was also evaluated using restriction enzyme digestion for A2058G and A2059G mutations (MboII and BsaI, respectively; New England BioLabs, Inc.) (25) . The DNA sequences were obtained using the DNA analyzer 3730xl (Applied Biosystems; Thermo Fisher Scientific, Inc.) and analyzed using DNASTAR ® software version 3.0 (DNASTAR Inc., Madison, WI, USA).
Antimicrobial susceptibility testing. All antibiotic disks (azithromycin) were purchased from Abtek Biologicals Ltd. (Liverpool, UK). An antibiogram was performed on Mueller-Hinton agar for 12 h at 37˚C to determine the antimicrobial agents resistance profiles to azithromycin (10 µg) or PBS (10 µg). Antimicrobial susceptibility was performed according to the European Committee on Antimicrobial Susceptibility guidelines (26) .
Statistical analysis. Data are expressed as mean ± standard deviation of triplicate experiments. All data were analyzed using SPSS 17.0 software (SPSS, Inc., Chicago, IL, USA). Differences among groups were analyzed by one-way analysis of variance with Tukey's multiple comparisons test. P<0.05 was considered to indicate a statistically significant difference.
Results
Comparison of the gene types of T. pallidum. DNA samples from 132 genital ulcer specimens were identified as T. pallidum positive, determined by PCR targeting the polA gene (Fig. 1A) . Three gene types were observed among the 132 T. pallidum positive specimens (Fig. 1B) . The restriction digestion assay indicated that 78 samples were tpr gene type, 24 were arp gene type and 30 were tp0548 gene type. These results suggest that tpr is the most common gene type of T. pallidum.
Analysis of T. pallidum drug resistance to azithromycin.
The antibiotic resistance of T. pallidum to azithromycin was analyzed in this study. As indicated in Fig. 2A , the restriction fragment length polymorphism analysis of the PCR amplicons from the representative samples (A2058G: 14a/f, 14e/f and 12e/f; A2059G: 8d/f, 12d/f, 6d/f, 11d/f, 14j/f.) revealed that 94 of the T. pallidum specimens were resistant to azithromycin. Gene type analysis indicated that the tpr gene type presented significantly higher drug resistance compared with the arp and tp0548 gene types (Fig. 2B) . These results suggest that tpr gene type may be associated with drug resistance of T. pallidum to azithromycin.
Comparison of the gene subtypes tpr of T. pallidum.
The association between gene subtype tpr of T. pallidum and drug resistance was evaluated further. Eight subtypes of tpr (14a/f, 14e/f, 12e/f, 12d/f, 6d/f, 11d/f, 14j/f, 8d/f) were identified among the 132 cases (Table I) . It was identified that 23S rRNA A2058G mutation was observed in gene subtypes 14a/f, 14e/f and 12e/f. A2059G mutation occurred in gene subtypes 8d/f, 12d/f, 6d/f, 11d/f and 14j/f. The proportion of azithromycin-resistant genotypes harboring either the A2058G or the A2059G mutation among T. pallidum was 65.8 and 34.2%, respectively (Fig. 3) . These results indicate that tpr gene subtypes of T. pallidum may be associated with drug resistance to azithromycin.
Analysis of drug resistance of A2058G and A2059G mutations in gene subtype tpr of T. pallidum.
The drug resistance of A2058G and A2059G mutations in gene subtype tpr of T. pallidum was investigated further. As indicated in Fig. 4A , A2059G mutation demonstrated a higher drug resistance for azithromycin compared with A2058G mutation, as determined by antimicrobial susceptibility test. The distribution of gene subtypes of T. pallidum with A2059G and A2058G mutation is presented in Fig. 4B and C. These results demonstrated that 14a/f of A2058G mutation and 12d/f of A2059G mutation frequently occurred in tpr of T. pallidum. These results indicate that A2058G and A2059G mutations in gene subtype tpr of T. pallidum are associated with drug resistance to azithromycin.
Discussion
Molecular subtyping for T. pallidum has previously been explored in the tpr gene and arp gene (27) . A previous study also indicated that azithromycin treatment failures are associated with resistance in T. pallidum (28) . However, the associations between molecular subtyping of T. pallidum and azithromycin resistance remain unclear. In the current study, the gene type of T. pallidum evaluated and azithromycin resistance was investigated in different gene types of T. pallidum.
The results indicate that out of 132 samples, 78 were tpr gene type, 24 were arp gene type and 30 were tp0548 gene type specimens of T. pallidum. The findings suggested that tpr gene type presented higher azithromycin resistance compared with arp and tp0548 gene type specimens of T. pallidum. Currently, azithromycin is widely used for the treatment of T. pallidum in patients that are allergic to penicillin (29) . Although the recommended azithromycin treatment for syphilis is effective, azithromycin resistance in T. pallidum has emerged and is increasing globally (30) . It was observed that T. pallidum has developed azithromycin resistance to a varying extent (29) . It has been identified that prevalence of azithromycin resistance is substantial in China and consequently that macrolides should not be used as a treatment option for early or incubating syphilis in China (31) . The results of the current study identified three gene types, tpr, arp and tp0548, in 132 T. pallidum positive specimens from the Yongkang region. Reports have also indicated that restriction fragment length polymorphisms are associated with the drug resistance of T. pallidum (32, 33) . In the current study, it was identified that 94 specimens of T. pallidum presented restriction fragment length polymorphisms, which were associated with drug resistance of T. pallidum for azithromycin. Notably, gene type analysis suggested that the tpr gene type presents higher drug resistance compared with the arp and tp0548 gene types of T. pallidum, which may be a potential target for addressing drug resistance to azithromycin.
A previous study indicated that tpr genes in T. pallidum are likely to be relevant to the pathogenesis of syphilis and drug resistance (34). A previous report described A2058G and A2059G mutations, which are associated with syphilis drug resistance to azithromycin (35) . In the present study, the drug resistance to azithromycin of A2058G and A2059G mutations in tpr gene types of T. pallidum were compared. It was indicated that A2059G mutation demonstrated higher drug resistance for azithromycin compared with A2058G mutation. The findings also revealed that the gene subtypes of T. pallidum 14a/f of A2058G mutation and 12d/f of A2059G frequently occurred in tpr of T. pallidum, which may be a potential target for the treatment of syphilis. A limitation of the present study was that it did not explore the clinical treatment of azithromycin for patients with T. pallidum.
In conclusion, the current study identified that 12d/f tpr gene type of T. pallidum is the most common gene type for drug resistance to azithromycin. The findings suggest that A2059G mutation is associated with azithromycin resistance. Further investigation is required into the molecular mechanism of drug resistance of T. pallidum.
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